Please login to the form below

Not currently logged in
Email:
Password:

ofatumumab

This page shows the latest ofatumumab news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand

Latest news

More from news
Approximately 6 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Option to acquire. 1250. GSK. Novartis. Arzerra [ofatumumab] anti CD20 monoclonal antibody in oncology indications.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics